<DOC>
	<DOC>NCT02361242</DOC>
	<brief_summary>PLEODIAL-II study is an extension of the previous pilot PLEODIAL-I study (CLN-PXT00864-03 protocol) and is designed for the descriptive analysis of patients with mild AD who are exposed to PXT00864 over an additional 24-week period.</brief_summary>
	<brief_title>24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion</brief_title>
	<detailed_description>Patients having completed the previous 12-week PLEODIAL-I study were eligible to receive PXT00864 in this 24-week open-label extension PLEODIAL-II study in order to collect some additional long-term data regarding the safety and the potential effect of PXT00864 on cognitive and behavioural impairments.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Main Mild Alzheimer's Disease patient who was included in PLEODIALI study Mini Mental State Examination (MMSE) score greater or equal to 20 Main Patient who was not compliant with the previous PLEODIALI study protocol Patient who experienced significant adverse events which necessitated treatment discontinuation during the PLEODIALI study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>PXT00864</keyword>
	<keyword>mild AD</keyword>
	<keyword>phase 2a</keyword>
</DOC>